Nobody can explain why Radient did many things.
But none of that matters now. All that matters is:
1. Radient's last patent for DR-70 expired and their last patent application for DR-70 was rejected and then abandoned. ANY entity wishing to manufacture and/or sell DR-70 can do so without compensating or asking permission from Radient.
2. When Radient "focused on DR-70 sales" they still couldn't sell enough to cover even 10% of their burn rate, and that's not counting loans, penalties, or interest. They basically burned $2 million a quarter on administrative and sales while generating $200,000 in revenues. Entities trying to market DR-70 today are probably experiencing similar results.
3. RXPC Share Registration was revoked in 2014 and the company's Officers promptly disappeared.
4. The Company's Officers transferred all the assets (meager as they were) away from Radient. They now claim all assets as property of their new company "Cancer Screen Technologies" in Hong Kong.
5. Attempts to contact and communicate with Radient's Officers resulted in those Officers blocking all North American ISP's from accessing their website cstamdl.com. You can access the website using a European or Asian proxy so we know it is still online - they simply seem to have "put their RXPC shareholders on Ignore."
So yes, it's amusing to watch what other entities are trying to do with DR-70. Unfortunately, none of it will benefit RXPC shareholders. There is no reason today to cut RXPC shareholders a piece of any DR-70 pie.
